Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.
about
Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the StartAdjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base.Evaluating surrogate marker information using censored data.Regression models for the restricted residual mean life for right-censored and left-truncated data.Targeted survival improvements in clinical trials: are you an absolutist or relativist?Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins.Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with "time to event" outcomesThe Role of Stage at Diagnosis in Colorectal Cancer Black-White Survival Disparities: A Counterfactual Causal Inference ApproachQuantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive BiomarkerRandomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial.Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.Restricted mean survival time over 15 years for patients starting renal replacement therapy.Discussion of "a risk-based measure of time-varying prognostic discrimination for survival models," by C. Jason Liang and Patrick J. Heagerty.Prognostic Value of Combined CT Angiography and Myocardial Perfusion Imaging versus Invasive Coronary Angiography and Nuclear Stress Perfusion Imaging in the Prediction of Major Adverse Cardiovascular Events: The CORE320 Multicenter Study.The impact of health insurance on cancer care in disadvantaged communities.Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.Quantifying the benefits of Mediterranean diet in terms of survival.On the restricted mean survival time curve in survival analysisAlternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.Reply to a note on the magnitude of hazard ratios.Reply to Osborne & Serdarevic (2017): Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans.Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.Design considerations in clinical trials with cure rate survival data: A case study in oncology.Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.Analysis of restricted mean survival time for length-biased data.Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
P2860
Q24289425-0F6C7F95-DAAD-47E5-AE7C-E6F4F67706E4Q31135072-3D635641-B8A2-459F-A52E-8FB3744A4033Q31154746-A6BDEC71-1ED1-4295-85A1-99B8F901F018Q31155584-5B555C52-2D96-4757-BFE8-DD0BCC10C5FAQ35084155-DDF574B8-EB50-4F89-B9D9-88A576AB169FQ35680027-50E43143-F624-4550-8438-F6FD1BCD46EAQ36051084-AB4F4CB6-4169-4CE7-B860-B86F4B728803Q36158851-7F5A3A59-7610-4DFD-A366-CC5A3B45E22FQ36216544-DA8C96A9-8BDA-4EE4-9E68-F72BBCC3AB1FQ36463929-59B0E561-449F-4299-A733-1CFC6D7749FFQ36868328-ECA710A0-2BF1-463A-9565-D03047A277ACQ37271002-1C1F48AE-50C1-441C-94DD-C8AF59286E6CQ38272671-243FB232-C3A7-49C8-8732-111B7457CAADQ38650382-6E317BC6-EBE5-4250-B42C-FA962E1A7FAFQ38688789-1A391A2E-8127-4419-8223-D4ADFD7E9A2DQ38722045-969FAC99-A7CC-42F0-93A7-292F5B414139Q38732370-F98DE88D-F10D-410B-A4BA-88D0A894BFC8Q38932579-E6FE4561-DCEC-4818-BB53-3D73ECF340AFQ39037219-FD0E6A03-222C-4069-85EB-EC441313AF5DQ39116925-CE615A46-8456-41D0-B9A9-3E5DAD983384Q39177420-2C2632E3-BC4E-4E2C-9AC9-E01BA09785DCQ39177934-3EF68B6E-C30E-4958-A693-B2C7A69B33DBQ39222626-9022FAF5-00C6-4CBF-9D2D-67BC3A1195F8Q39350574-7BE5B1F6-0BDC-40DB-A6DC-A6C2C0A29973Q39502355-417202F7-4ABB-477A-ADF0-CE668AE5BB5CQ40020831-B12A4908-2234-442E-8BAD-73101CDE700DQ40612925-22EE2A4B-62D4-4DB2-9986-85ECCD3971ECQ40858704-D7BA8E9E-E8B1-4780-AEC3-5FA9AA0C9F03Q42336240-2DEDC093-C57A-41D4-B60E-9548F7E20104Q43146952-9DD343C0-E64B-4A5D-84A3-632EBD6733A5Q43606699-296D2CB6-EC4A-4908-8637-1680C0776E67Q45326558-561F4CC6-B813-4271-AA24-EE34F5741FD1Q45933560-FF43D072-63D9-4394-99AC-0EBB28CEBD2AQ46710975-9C7FFD99-B108-4999-9CEF-05CE7522D1B8Q47104846-296CB456-8570-40FF-9AAC-9F94903F9158Q47280582-B3370134-8483-4221-B0D1-B358AEC9DAA5Q47437336-841EDC63-A493-4922-BCAB-FF615E92D22FQ47570953-94BE2B31-CD6A-484F-9FC2-E3ACEBD2AFB8Q47693886-CBD7589A-D34A-4882-A46E-AB7F3E8CA391Q47916230-37F72D8E-B3C2-4E4C-8BA3-11BFDEFA1498
P2860
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Moving beyond the hazard ratio ...... fference in survival analysis.
@ast
Moving beyond the hazard ratio ...... fference in survival analysis.
@en
type
label
Moving beyond the hazard ratio ...... fference in survival analysis.
@ast
Moving beyond the hazard ratio ...... fference in survival analysis.
@en
prefLabel
Moving beyond the hazard ratio ...... fference in survival analysis.
@ast
Moving beyond the hazard ratio ...... fference in survival analysis.
@en
P2093
P2860
P356
P1476
Moving beyond the hazard ratio ...... fference in survival analysis.
@en
P2093
Brian Claggett
Deborah Schrag
Eisuke Inoue
Lee-Jen Wei
Lihui Zhao
Masahiro Takeuchi
Michael Hughes
Milton Packer
Paul Gallo
P2860
P304
P356
10.1200/JCO.2014.55.2208
P407
P577
2014-06-30T00:00:00Z